ABSTRACT
The evolution of language models, particularly the development of Large Language Models like ChatGPT, has opened new avenues for psychological assessment, potentially revolutionizing the rating scale methods that have been used for over a century. This study introduces a new Automated Assessment Paradigm (AAP), which aims to integrate natural language processing (NLP) techniques with traditional measurement methods. This integration enhances the accuracy and depth of mental health evaluations, while also addressing the acceptance and subjective experience of participants—areas that have not been extensively measured before. A pilot study was conducted with 32 participants, seven of whom were diagnosed with depression by licensed psychiatrists using the Clinical Interview Schedule-Revised (CIS-R). The participants completed the BDI-Fast Screen (BDI-FS) using a custom ChatGPT (GPTs) interface and the Chinese version of the PHQ-9 in a private setting. Following these assessments, participants also completed the Subjective Evaluation Scale. Spearman’s correlation analysis showed a high correlation between the total scores of the PHQ-9 and the BSI-FS-GPTs. The agreement of diagnoses between the two measures, as measured by Cohen’s kappa, was also significant. BSI-FS-GPTs diagnosis showed significantly higher agreement with the current diagnosis of depression. However, given the limited sample size of the pilot study, the AUC value of 1.00 and a sensitivity of 0.80 at a cutoff of 0.5, with zero false positive rate, likely overstate the classifier’s performance. Bayesian factors suggest that participants may feel more comfortable expressing their true feelings and opinions through this method. For ongoing follow-up research, a total sample size of approximately 104 participants, including about 26 diagnosed individuals, may be required to ensure the analysis maintains a necessary power of 0.80 and an alpha level of 0.05. Nonetheless, these findings provide a promising foundation for the ongoing validation of the new AAP in larger-scale studies, aiming to confirm its validity and reliability.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been reviewed and approved by the Ethics and Academic Special Committee of Zhengzhou Normal University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://osf.io/atq53/